Overview

Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)

Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
This is a 2-arm, randomized, double-blind, double-dummy, and controlled clinical study, with 6 months of treatment to evaluate the clinical and metabolic efficacy of DLBS3233 in improving reproductive parameters and to evaluate the safety of DLBS3233 in women with polycystic ovary syndrome compared with metformin, as an active control.
Phase:
Phase 3
Details
Lead Sponsor:
Dexa Medica Group
Treatments:
Metformin